USFDA approves Pfizer’s Litfulo for adults and adolescents with severe alopecia areata
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The company will submit its comprehensive response on these observations to the USFDA
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This product will be manufactured at Lupin's Pithampur facility in India
Dignitaries and delegates commend India’s leadership in Global South during G20 India Presidency
The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence
Subscribe To Our Newsletter & Stay Updated